Add to Twitter

Dubai Design District, d3, to Unveil Inspiring New Masterplan at Cityscape Global 2014
September 19, 2014

Dubai Design District (d3) is set to unveil its master plan on the opening day of Cityscape Global, Sunday 21st September. Spanning a total area of 21 million square feet, the official master plan offers a preview of what Dubai’s new cornerstone of creativity will look like once complete, and insight into what d3 will deliver to the region’s growing design, fashion, art and luxury sectors over"...

Al Ain Traffic Boosts its Efforts to Raise the Awareness of Pilgrims Travelling by Land
September 19, 2014

The Traffic and Patrols Directorate at Abu Dhabi Police intensified its efforts to boost awareness of pilgrims travelling by land. As a part of the measures undertaken in this regard, the directorate has allocated an area within the pilgrims’ tent at Al Ghuweifat border point to offer assistance to pilgrims’ transport companies from inside and outside the UAE and provide drivers with tips and"...

ADP Motivate Emirates Driving Company Employees and Students to Learn First Aid
September 19, 2014

The Emergency and Public Safety Department at Abu Dhabi Police has called on both employees and students of the Emirates Driving Company to learn basic first aid techniques and tips and how to apply them using the necessary equipment; so as to avoid any complications that may be associated with medical emergency conditions and to save the life of others.

September 19, 2014

The General Directorate of Residency and Foreigners Affairs in Abu Dhabi called upon employees at Baniyas Passports Office to fulfill their job requirements quickly and accurately, streamline procedures, enhance performance with a view to upgrade work standards to the highest levels, and provide distinguished services to the public.

These remarks were made by Colonel Salim"...

September 19, 2014
  • Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202
  • CV9202 is based on CureVac’s mRNA technology (RNActive®)
  • Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting
  • The in-licensing of this investigational cancer compound adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer...